All News

The use of cryoablation, rather than radiofrequency (RF) ablation for the treatment of small renal masses may be controversial for some urologists, but recent data support the superiority of cryoablation.

The concept of physicians demanding and getting stipends for being on call at hospital emergency rooms is becoming a well-established trend that many feel will eventually reach into all hospitals. Urologists are no exception.

The mainstay of treatment for men with metastatic prostate cancer, gonadotropin-releasing hormone (GnRH) agonists are also the subject of recent studies showing that they raise the risk of such adverse effects as diabetes and cardiovascular disease.

Developments in stem cell therapy, new minimally invasive sling procedures, and research on botulinum toxin (Botox) therapy for overactive bladder soon will give urologists far more effective treatment for incontinence than they can offer their patients today.

A baseline bone density test to screen for osteoporosis, simple lifestyle changes to prevent osteoporosis from developing, and aggressive treatment if it develops are strongly recommended for men on androgen deprivation therapy (ADT) for advanced prostate cancer.

Basic research should soon bring urologists entirely new ways to thwart or treat urinary tract infection, which could be welcome eleventh-hour saves from the problem of antibiotic-resistant bacteria.

The 2007 AUA Annual Meeting begins May 19th at the Anaheim Convention Center in Anaheim, California. In this podcast, Richard Kerr, the editor-in-chief of Urology Times provides us with an overview of the meeting and Elaine Cali, VP of Communications for the Anahiem/Orange County Visitors and Convention Bureau shares a few ideas for making your visit to Southern California fun for the whole family.

David A. Bloom, MD, has been appointed chairman of the department of urology at the University of Michigan Medical School in Ann Arbor. Dr. Bloom, a pediatric urologic surgeon who is the Jack Lapides Professor of Urology, replaces James E. Montie, MD, who relinquished the chairmanship to continue his research on the quality of care for patients with urologic cancer.

Cosmos Trading, Inc., is conducting a voluntary nationwide recall of its dietary supplement product sold under the name Rhino Max (Rhino V Max) after lab analysis found that the product contains aminotadalafil, an analogue of tadalafil, making Rhino Max (Rhino V Max) an unapproved drug.

The American Association for Cancer Research (AACR) has announced the formation of the AACR-FDA-NCI Cancer Biomarkers Collaborative to facilitate the use of validated biomarkers in clinical trials and, ultimately, their use in evidence-based oncology and cancer medicine. The collaborative includes researchers from academia, government, and industry, as well as patient advocacy groups.